Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
- PMID: 11941374
- DOI: 10.1038/nn842
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
Abstract
We have previously shown that chronic treatment with the monoclonal antibody m266, which is specific for amyloid beta-peptide (Abeta), increases plasma concentrations of Abeta and reduces Abeta burden in the PDAPP transgenic mouse model of Alzheimer's disease (AD). We now report that administration of m266 to PDAPP mice can rapidly reverse memory deficits in both an object recognition task and a holeboard learning and memory task, but without altering brain Abeta burden. We also found that an Abeta/antibody complex was present in both the plasma and the cerebrospinal fluid of m266-treated mice. Our data indicate that passive immunization with this anti-Abeta monoclonal antibody can very rapidly reverse memory impairment in certain learning and memory tasks in the PDAPP mouse model of AD, owing perhaps to enhanced peripheral clearance and (or) sequestration of a soluble brain Abeta species.
Similar articles
-
An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.Neurobiol Dis. 2009 Dec;36(3):425-34. doi: 10.1016/j.nbd.2009.08.007. Epub 2009 Aug 22. Neurobiol Dis. 2009. PMID: 19703562
-
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. doi: 10.1073/pnas.151261398. Epub 2001 Jul 3. Proc Natl Acad Sci U S A. 2001. PMID: 11438712 Free PMC article.
-
Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.Autoimmun Rev. 2006 Jan;5(1):33-9. doi: 10.1016/j.autrev.2005.06.007. Epub 2005 Aug 1. Autoimmun Rev. 2006. PMID: 16338209 Review.
-
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.Science. 2002 Mar 22;295(5563):2264-7. doi: 10.1126/science.1067568. Science. 2002. PMID: 11910111
-
Amyloid-beta immunotherapies in mice and men.Alzheimer Dis Assoc Disord. 2006 Apr-Jun;20(2):118-23. doi: 10.1097/01.wad.0000213810.89681.a5. Alzheimer Dis Assoc Disord. 2006. PMID: 16772748 Review.
Cited by
-
The case for rejecting the amyloid cascade hypothesis.Nat Neurosci. 2015 Jun;18(6):794-9. doi: 10.1038/nn.4017. Nat Neurosci. 2015. PMID: 26007212 Review.
-
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.Acta Neuropathol. 2015 Feb;129(2):183-206. doi: 10.1007/s00401-015-1386-3. Epub 2015 Jan 22. Acta Neuropathol. 2015. PMID: 25604547 Free PMC article. Review.
-
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.J Neuroimmunol. 2013 Jan 15;254(1-2):63-8. doi: 10.1016/j.jneuroim.2012.09.008. Epub 2012 Oct 1. J Neuroimmunol. 2013. PMID: 23036592 Free PMC article.
-
Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease.Alzheimers Res Ther. 2013 May 24;5(3):28. doi: 10.1186/alzrt182. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 23705774 Free PMC article.
-
Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment.Int J Mol Sci. 2021 May 24;22(11):5549. doi: 10.3390/ijms22115549. Int J Mol Sci. 2021. PMID: 34074018 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases